ASX 200 Stock Mesoblast Indicating Substantial Growth Pipeline
This undervalued ASX 200 stock has experienced massive growth in revenue but still appears undervalued relative to its future potential and investors should pay close attention to the upcoming catalysts that could further unlock shareholder value.
Mesoblast Limited (ASX: MSB)
Mesoblast Limited (ASX: MSB) is now viewed by investors as an undervalued ASX 200 stock because of its massive commercial potential and it also announced an impressive half year result on 27 February 2026 which marked a clear turning point as it became a revenue generating commercial business.
The company's main product Ryoncil treats paediatric steroid refractory acute graft versus host disease which received FDA approval in December 2024.
The company in H1 FY26 reported total revenue of US$51.3 million which is a sharp rise from US$3.2 million a year earlier due to the successful U.S. launch of Ryoncil that generated US$48.7 million in net product sales.
Gross profit from Ryoncil reached US$44.2 million which shows strong early demand and highlights the high margin profile of its first FDA approved allogeneic mesenchymal stromal cell therapy.
The company reported a net loss of US$40.2 million which improved from US$47.9 million in the prior period because operating leverage began to appear as revenue increased.
Cash at 31 December 2025 stood at US$130 million and Mesoblast secured a new US$125.0 million non-dilutive credit facility which improved liquidity and provided funding flexibility for late-stage programs.
Management expects FY2026 Ryoncil net revenue to fall between US$110 million and US$120 million which suggests solid momentum in the second half of the year.
In chronic low back pain, the confirmatory 300 patient Phase 3 trial is recruiting across 40 U.S. sites which follows positive FDA feedback that a single pivotal trial that shows clinically significant pain reduction at 12 months can support approval.
Next major catalysts include 3Q26 revenues in mid-March along with completion of enrolment for the chronic lower back pain Phase 3 trial by March or April and submission of the BLA for Revascor in the June quarter.
If upcoming data and regulatory milestones are positive, this undervalued ASX 200 stock could experience a major rally ahead.
(Source: Company Announcements)
Get Your Free Report on Top 5 ASX Stocks on WhatsApp
Instant Access. No Credit Card Required.
Receive on WhatsApp
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialASX Stock Research & Recommendations — 7‑day free trial
Independent, analyst‑driven insights.
- Stock of the week report
- Daily Analysis Report
- No credit card required
Get Your FREE Report
Discover the Top ASX Stocks to Invest In 2026!
Expert Analysis of Top-Performing ASX Stocks
Market Insights and In-Depth Research
Buy, Sell, And Hold Recommendations
Almost There!
Enter your details to download the report
Success!
Preparing your download...
Latest Article
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
